Premium
ReishiMax extends the lifespan in an aging model: A preliminary report
Author(s) -
Tan Ningzhi,
Zhang Yan,
Yang Jieying,
Zhao Chunsheng,
Zhu JiaShi
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.738.5
Subject(s) - immune system , medicine , cd8 , cancer , gastroenterology , immunology , traditional medicine
Ganoderma lucidum (Reishi) has long been used as a medicinal herb in China for immune enhancement and cancer prevention and adjuvant therapy. ReishiMax (RM), a proprietary extract of Reishi enriched in Reishi triterpenes and polysaccharides showed immune enhancement (enhanced proliferations of macrophages, B, T and NK lymphocytes, increases in serum IgA, IgG, IgM & secretion of IL2 and Interferon, and decreases in IL5 secretion) and inhibition of cancer malignancy (FASEB J 2007, 21:A1100; 2008, 22:1136.2). We further examined the RM's effect in lifespan extension in mice. ICR mice (12 m of age; 25 males & 25 females) were randomized into 4 groups, receiving either rat chaw alone or the forage prior mixed with RM at a dose of 175, 350 or 700 mg/kg. Calorie intake was monitored twice a week and adjusted to match the calorie intake of controls. RM treatment (36 wks so far) showed: (1) no significant differences in body weight and calorie intake among the groups; (2) compared to controls, the 90% survival time extends 20, 56 and 44 days in the 3 RM dose groups, and the 75% survival time extends 21, 70 and 24 days, respectively. Kaplan‐Meier Survivor analysis showed significantly extended lifespan and reduced death risks by RM: p=0.048 (Wk28), p=0.045 (Wk32), p=0.022 (Wk36), with the best survivor curve for the RM 350 mg/kg therapy (equivalent to the human dose). The data thus far indicates that RM extends the lifespan in mice.